JP2024517618A5 - - Google Patents
Info
- Publication number
- JP2024517618A5 JP2024517618A5 JP2023563172A JP2023563172A JP2024517618A5 JP 2024517618 A5 JP2024517618 A5 JP 2024517618A5 JP 2023563172 A JP2023563172 A JP 2023563172A JP 2023563172 A JP2023563172 A JP 2023563172A JP 2024517618 A5 JP2024517618 A5 JP 2024517618A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- optionally
- lymphoma
- leukemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174818P | 2021-04-14 | 2021-04-14 | |
| US63/174,818 | 2021-04-14 | ||
| US202163215760P | 2021-06-28 | 2021-06-28 | |
| US63/215,760 | 2021-06-28 | ||
| US202163288078P | 2021-12-10 | 2021-12-10 | |
| US63/288,078 | 2021-12-10 | ||
| US202263329560P | 2022-04-11 | 2022-04-11 | |
| US63/329,560 | 2022-04-11 | ||
| PCT/US2022/024725 WO2022221478A1 (en) | 2021-04-14 | 2022-04-14 | Binding proteins recognizing ha-2 antigen and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517618A JP2024517618A (ja) | 2024-04-23 |
| JP2024517618A5 true JP2024517618A5 (enExample) | 2025-04-22 |
Family
ID=83640691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563172A Pending JP2024517618A (ja) | 2021-04-14 | 2022-04-14 | Ｈａ－２抗原を認識する結合タンパク質及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197877A1 (enExample) |
| EP (1) | EP4322971A4 (enExample) |
| JP (1) | JP2024517618A (enExample) |
| KR (1) | KR20230170704A (enExample) |
| AU (2) | AU2022204581B2 (enExample) |
| BR (1) | BR112023021034A2 (enExample) |
| CA (1) | CA3215276A1 (enExample) |
| IL (1) | IL307429A (enExample) |
| MX (1) | MX2023012111A (enExample) |
| TW (1) | TW202313670A (enExample) |
| WO (1) | WO2022221478A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4626915A2 (en) * | 2022-11-29 | 2025-10-08 | Bluesphere Bio, Inc. | T cell receptors targeting minor histocompatibility antigen ha-2 |
| WO2024148212A2 (en) * | 2023-01-06 | 2024-07-11 | The Trustees Of The University Of Pennsylvania | T cell receptors directed to sox2 protein |
| TW202449156A (zh) | 2023-05-18 | 2024-12-16 | 美商克雷德治療股份有限公司 | 抑制天然殺手細胞對細胞療法之細胞毒性 |
| WO2025217035A2 (en) * | 2024-04-08 | 2025-10-16 | Tscan Therapeutics, Inc. | Use of anti-ha-1 and anti-ha-2 binding proteins for treatment of aml, all, and mds |
| TW202547854A (zh) * | 2024-04-08 | 2025-12-16 | 美商帝斯肯醫療公司 | Ｍａｇｅｃ２免疫原性肽、識別ｍａｇｅｃ２免疫原性肽之結合蛋白及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259181T3 (es) * | 1995-07-25 | 2006-09-16 | Rijksuniversiteit Te Leiden | Peptido antigenico ha-2. |
| AU2002366951A1 (en) * | 2001-12-10 | 2003-07-09 | Nuvelo,Inc. | Novel nucleic acids and polypeptides |
| HRP20171164T1 (hr) * | 2010-09-20 | 2017-10-20 | Biontech Cell & Gene Therapies Gmbh | Antigen-specifični t stanični receptori i t stanični epitopi |
| AU2012309830B2 (en) * | 2011-09-15 | 2017-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage |
| MX2019003768A (es) * | 2016-10-03 | 2019-06-24 | Juno Therapeutics Inc | Moleculas de enlace especificas de hpv. |
| JP7037577B2 (ja) * | 2017-03-15 | 2022-03-16 | フレッド ハッチンソン キャンサー リサーチ センター | 高親和性ｍａｇｅ－ａ１特異的ｔｃｒ及びその使用 |
| EP3773908A1 (en) * | 2018-04-05 | 2021-02-17 | Juno Therapeutics, Inc. | T cell receptors and engineered cells expressing same |
| EP3670530A1 (en) * | 2018-12-18 | 2020-06-24 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies |
| MX2021010840A (es) * | 2019-03-08 | 2022-01-19 | Obsidian Therapeutics Inc | Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable. |
| EP3962939A4 (en) * | 2019-05-03 | 2023-05-17 | Gigamune, Inc. | MODIFIED CELLS EXPRESSING ANTITUMOR T-LYMPHOCYTE RECEPTORS AND METHODS OF USING THEM |
-
2022
- 2022-04-14 AU AU2022204581A patent/AU2022204581B2/en active Active
- 2022-04-14 EP EP22788902.9A patent/EP4322971A4/en active Pending
- 2022-04-14 TW TW111114218A patent/TW202313670A/zh unknown
- 2022-04-14 JP JP2023563172A patent/JP2024517618A/ja active Pending
- 2022-04-14 MX MX2023012111A patent/MX2023012111A/es unknown
- 2022-04-14 US US18/286,726 patent/US20240197877A1/en active Pending
- 2022-04-14 WO PCT/US2022/024725 patent/WO2022221478A1/en not_active Ceased
- 2022-04-14 CA CA3215276A patent/CA3215276A1/en active Pending
- 2022-04-14 KR KR1020237038120A patent/KR20230170704A/ko active Pending
- 2022-04-14 IL IL307429A patent/IL307429A/en unknown
- 2022-04-14 BR BR112023021034A patent/BR112023021034A2/pt unknown
-
2023
- 2023-07-13 AU AU2023204645A patent/AU2023204645A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517618A5 (enExample) | ||
| AU2021200388B2 (en) | Methods of isolating T cell receptors having antigenic specificity for a cancer specific mutation | |
| JP7270001B2 (ja) | Ｍｈｃクラスｉｉ拘束性ｍａｇｅ－ａ３を認識するｔ細胞受容体 | |
| Beyar-Katz et al. | Novel approaches to acute myeloid leukemia immunotherapy | |
| JP2023549765A5 (enExample) | ||
| JP7770188B2 (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| MacDonald et al. | Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor | |
| Guzylack-Piriou et al. | Membrane markers of the immune cells in swine: an update | |
| Behar et al. | Diverse TCRs recognize murine CD1 | |
| Biernacki et al. | T-cell receptor–based immunotherapy for hematologic malignancies | |
| Mingari et al. | HLA-class I-specific inhibitory receptors in human cytolytic T lymphocytes: molecular characterization, distribution in lymphoid tissues and co-expression by individual T cells. | |
| CN107847585B (zh) | 用于得到体内存留性和治疗活性的nkt细胞亚群以及其繁殖 | |
| JP2023534808A (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| CA3144070A1 (en) | T cell receptors recognizing r175h or y220c mutation in p53 | |
| US12365717B2 (en) | Specific t cell receptors against epitopes of mutant MYD88L265P protein for adoptive T cell therapy | |
| JP2024546018A5 (enExample) | ||
| JP2024515646A5 (enExample) | ||
| Zambello et al. | Natural killer receptors in patients with lymphoproliferative diseases of granular lymphocytes | |
| Müller et al. | Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells | |
| US12364757B2 (en) | TCR and uses thereof | |
| Chen et al. | Generation of effective and specific human TCRs against tumor/testis antigen NY-ESO-1 in mice with humanized T cell recognition system | |
| Chmielowski et al. | In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities | |
| Hioki et al. | The mosquito effect: regulatory and effector T cells acquire cytoplasmic material from tumor cells through intercellular transfer | |
| US20240360236A1 (en) | Methods for targeted immunotherapy of acute myeloid leukemia (aml) | |
| EP4491630A1 (en) | T-cell receptor for acute myeloid leukemia (aml) |